Robert W. Baird Issues Positive Forecast for GRAIL (NASDAQ:GRAL) Stock Price

GRAIL (NASDAQ:GRAL) had its target price boosted by analysts at Robert W. Baird from $96.00 to $118.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would indicate a potential upside of 9.29% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. TD Cowen reiterated a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Mizuho boosted their target price on shares of GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Wolfe Research began coverage on shares of GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Finally, UBS Group set a $84.00 price target on shares of GRAIL in a research note on Thursday. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, GRAIL currently has a consensus rating of “Hold” and an average price target of $75.10.

GRAIL Price Performance

Shares of NASDAQ GRAL opened at $107.97 on Tuesday. GRAIL has a 1 year low of $41.50 and a 1 year high of $118.84. The firm has a 50-day simple moving average of $74.85 and a two-hundred day simple moving average of $63.93. The company has a market cap of $4.82 billion, a P/E ratio of -11.07 and a beta of 3.25.

GRAIL (NASDAQ:GRAL) last released its earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%.The firm had revenue of $44.69 million for the quarter, compared to analysts’ expectations of $42.39 million. As a group, equities research analysts expect that GRAIL will post -10.41 EPS for the current year.

Insider Buying and Selling at GRAIL

In other news, CEO Joshua J. Ofman sold 5,000 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $85.02, for a total transaction of $425,100.00. Following the transaction, the chief executive officer owned 397,271 shares of the company’s stock, valued at approximately $33,775,980.42. This represents a 1.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 7,900 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $85.01, for a total value of $671,579.00. Following the transaction, the chief financial officer owned 253,083 shares in the company, valued at approximately $21,514,585.83. This represents a 3.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.83% of the company’s stock.

Institutional Investors Weigh In On GRAIL

Several large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company boosted its stake in shares of GRAIL by 26.3% during the second quarter. The Manufacturers Life Insurance Company now owns 21,597 shares of the company’s stock valued at $1,474,000 after purchasing an additional 4,498 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of GRAIL during the 2nd quarter worth $82,000. Arizona State Retirement System boosted its position in GRAIL by 8.6% during the second quarter. Arizona State Retirement System now owns 10,470 shares of the company’s stock valued at $715,000 after purchasing an additional 833 shares in the last quarter. Nykredit A S purchased a new position in GRAIL in the second quarter valued at about $96,000. Finally, HighTower Advisors LLC lifted its position in shares of GRAIL by 3.5% during the second quarter. HighTower Advisors LLC now owns 40,565 shares of the company’s stock valued at $2,769,000 after buying an additional 1,357 shares during the last quarter.

Key Stories Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: FDA staff reportedly identified no major concerns with Galleri and broadly supported the test’s clinical performance, helping revive expectations that the product could clear the regulatory process. Grail rallies as FDA staff flags no major concerns for multi-cancer test
• Positive Sentiment: The briefing documents highlighted Galleri’s high accuracy and low false-positive rate, key factors that could support a favorable advisory-panel discussion and eventual approval. Low False Positives and High Accuracy: FDA Document Fueling Grail Stock Surge
• Positive Sentiment: Investors viewed the FDA materials as materially improving Galleri’s approval prospects, driving a broad reassessment of GRAIL’s valuation and sending the stock back above $100. GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes
• Neutral Sentiment: The FDA advisory committee meeting remains the immediate catalyst. Panel feedback can influence the agency, but it is not the same as final FDA approval; the outcome could determine whether Galleri becomes a commercially significant product for GRAIL. GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
• Negative Sentiment: The rally leaves GRAIL exposed to substantial event-driven volatility. Any unfavorable panel recommendation, requests for additional data, or delays could reverse the recent gains, while the company remains unprofitable and dependent on regulatory and commercial execution.

GRAIL Company Profile

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.